NASDAQ · Biotechnology · USD

Instil Bio, Inc. (TIL) Stock Analysis

Instil Bio, Inc. (TIL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

TIL

$5.77

−$0.17 (−2.86%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TIL with… →

TIL Key Statistics

As of Oct 21, 2026

Trading

Open: $6.01
Previous Close: $5.94
Day's Range: 5.73–6.09
52-Week Range: 5.62–20.11
Volume: 40.87K
Beta: 1.94

Valuation

Market Cap: $39.13M
P/E Ratio: unprofitable
EPS (ttm): −4.43

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$71.37M
Shares Outstanding: 6.78M
1-Year Return: −69.63%

Dividend and dates

Avg Volume: 17.56K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, TIL closed at $5.77, −69.63% over 1 year.

Instil Bio, Inc. (TIL) has a market capitalization of $39.13M.

In fiscal 2025, TIL reported revenue of $0.00.

TIL Stock Return by Calendar Year

Instil Bio, Inc. (TIL) return since Mar 2021: what $10,000 became

1 year: $10,000 $3,037; −69.63%
5 years: $10,000 $159; −98.41%
Since Mar 2021: $10,000 $109; −98.91%

If you had invested $10,000 in Instil Bio, Inc. (TIL) at the close on March 19, 2021, the earliest close on record here, it would have been worth $109 at the close on October 21, 2026: −98.91% in total, −55.43% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−35.29%−96.32%−39.52%+150.52%−42.38%−47.55%

2021*20222023202420252026*

Year	Return
2026 (partial year)	−47.55%
2025	−42.38%
2024	+150.52%
2023	−39.52%
2022	−96.32%
2021 (partial year)	−35.29%

As of October 21, 2026.

TIL Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$71.37M	—
2024	$0.00	−$74.14M	—
2023	$0.00	−$156.09M	—
2022	$0.00	−$223.18M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$51.96M	−$71.37M	—
2024	$0.00	—	−$56.05M	−$74.14M	—
2023	$0.00	—	−$87.16M	−$156.09M	—
2022	$0.00	—	−$203.29M	−$223.18M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Analysis

Data-derived

Company Overview

Instil Bio, Inc. (TIL) carries a market capitalisation of $39.13M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 17 employees.

TIL last closed at $5.77 on October 21, 2026. That is −$0.17 (−2.86%) against the previous close. Over the past 52 weeks the price has ranged from $5.62 to $20.11. The latest close sits 2.67% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $71.37M. Earnings per share on a trailing basis come to −4.43.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year total return is −69.63%. Across 5 years the annualized return works out at −56.31%. Beta against the wider market is reported at 1.94. Daily returns over the trailing 5 years annualize to a volatility of 106.1%.

Growth & Income

The record shows no dividend for TIL.

Across the complete calendar years on file, 2024 returned +150.52% and 2022 returned −96.32%. Of the 4 complete calendar years on file, 1 finished higher. 2026 is still running; the total return is −47.55% year to date.

Peer Comparison

Instil Bio, Inc. (TIL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Instil Bio, Inc.	TIL	$39.13M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. Instil Bio, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Instil Bio, Inc.

Instil Bio, Inc., a biopharmaceutical company, focuses on identifying and advancing therapeutic opportunities. It seeks to in-license or acquire and develop additional novel therapeutic candidates in diseases with significant unmet medical need. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.

Visit website →